With only one manufacturer, Actavis, Malta hardly seems destined to become the next pharmaceutical manufacturing hotbed. However, its government has paved the way for introduction of more generics. In fact, competitors can start developing products six years after a pharmaceutical company first applies for authorisation to market a new drug, so generics can be sold even while the branded drug is still patent-protected.
Now, the tiny nation of 400,000, the smallest and one of the newest members of the E.U., has its own market study. Research and Markets has just released a new report on the potential of the Maltese pharmaceutical market.
-- PWT
